Running rare disease clinical trials is difficult and prone to hurdles. When we worked on a three-part dosing study for Primary Sclerosing Cholangitis (PSC), a rare progressive liver disease, and noted recruitment delays in the second part of the study, we took action to keep the trial timelines intact.
Read the full case study to see how we made this happen.
